ImpediMed Limited
Suite 31C, 12-18 Tryon Rd
Lindfield NSW 2070
Australia
E: investorrelations@impedimed.com
W : impedimed.com

30 April 2026

Companies Announcements Office
Australian Securities Exchange

Quarterly Activity and Cash Flow Report

Key highlights for Q3 FY26

- Revenue of $3.5 million
- Annual Recurring Revenue of $14.1 million ($14.9 million constant currency)
- SOZO® Core Business TCV of $5.4 million
- Cash receipts of $3.3 million
- Net operating cash outflows of $4.5 million
- Cash balance of $12.7 million
- BCRL – Reimbursement continues to increase with, 328M U.S. covered lives, 94.3% national coverage, up from 92.8% at Q2 FY26
- Commercial activities in Heart Health and Weight Management commenced in the US with initial sales in both markets
- Appointment of new Managing Director / CEO, Erik Anderson, on 7 April 2026

ImpediMed Limited (ASX.IPD) (**ImpediMed** or the **Company**) announces the release of the Quarterly Activities Report and Appendix 4C Cash Flow Report for the quarter ending 31 March 2026 (Q3 FY26).

ImpediMed continues to be well positioned to capitalise on opportunities across multiple indications, leveraging its investment in a world-class digital health platform, FDA clearances in Breast Cancer Related Lymphoedema (BCRL), Heart Health and Body Composition, alongside growing patient needs in cancer survivorship, GLP-1 driven weight management and heart failure.

Supported by NCCN and NAPBC guidelines, SOZO drives strong clinical demand by enabling early detection and timely intervention that prevents lymphoedema progression — with expanding reimbursement continuing to accelerate commercialisation.

Reimbursement continued to increase during the quarter. National coverage now stands at 94.3%, representing 328 million covered lives - up from 92.8% reported with Q2 FY26 results. Significantly, the number of states with coverage above 95% has grown to 37, an increase of 17 states since 1 December 2025. There are now 49 states with coverage above

80% and 45 states above 90%, This progress fuels both new customer acquisition and re-engagement with existing accounts, giving our clinical teams a concrete reason to help our customers unlock additional utilisation across the installed base.

617 SOZO units are installed at leading US hospitals, and Master Services Agreements (MSAs) have been signed with 27 major Integrated Delivery Networks (IDNs), streamlining IT approvals and enabling the Company to rapidly access opportunities in BCRL, Heart Health and Body Composition.

Heart Health

Commercialisation of SOZO Pro into the highly attractive Heart Health market commenced with the establishment of a small, dedicated team with initial sales recorded in the quarter.

SOZO Pro is the only FDA-cleared BIS device for patients with cardiac implantable devices and commercialisation efforts are initially focused in select states where the SOZO Pro is reimbursed by private payers. SOZO Pro has also received a Medicare National Coverage Determination (~75% heart failure patients on Medicare).

The US outpatient heart failure fluid monitoring market represents a total addressable market of US$600 million with demand driven by urgent need to reduce readmissions and monitor Body Composition. There are 6.7 million US patients with heart failure with approximately 1 million new heart failure patients diagnosed each year.

Weight Management

Body composition monitoring represents a significant and expanding opportunity, and as GLP-1 therapies drive unprecedented patient volumes, clinicians are discovering that weight alone is an insufficient measure of treatment success. SOZO fills that gap with precision. Sales activities in the Weight Management market have commenced following the establishment of a small, dedicated team, with initial sales recorded in the quarter.

Appointment of new CEO

On 7 April 2026, Mr Erik Anderson commenced as Managing Director and Chief Executive Officer. Prior to joining ImpediMed, Mr Anderson served as Division President of Hologic's Breast and Skeletal Health business, a global leader across the breast cancer care continuum — spanning detection, intervention and surgery, with strong engagement across breast radiologists and surgeons in US health systems.

Mr Anderson brings proven expertise across US healthcare delivery, including hospital procurement, clinical adoption, reimbursement, and health system relationships, combined with a track record of building high-performing teams and translating strategic vision into commercial results. His experience spans not only revenue growth and market development, but the operational and organisational foundations that make growth sustainable.

Mr Anderson's appointment represents a step change in the Company’s ‘on the ground’ leadership presence in the critical United States market, with a clear mandate to accelerate revenue, strengthen health system engagement, control costs, and drive the Company toward cash flow break-even and long-term value creation.

Key sales and financial metrics

Unaudited total revenue for the quarter was $3.5 million, down 10% compared with Q2 FY26. The lower revenue was due to ROW distributor restocking in the previous quarter and the impact of a stronger Australian dollar. On a constant currency basis U.S. revenue was up 2% compared with Q2 FY26.

A total of 36 SOZO units were sold in the quarter with 30 units sold in the US (19 units in Q2 FY26) and 6 units sold in the ROW markets (38 units in Q2 FY26). The reduction in unit sales in the ROW markets was due to a stocking order of SOZO Pro units in the previous quarter by ImpediMed's Australian distributor in preparation for the Company's expansion into Heart Health.

Core Business Total Contracted Value (TCV) signed during the quarter was $5.4 million, compared with $4.1 million achieved in Q2 FY26.

Core Business Annual Recurring Revenue (ARR) was $14.1 million for the 12 months to 31 March 2027. ARR was impacted by a relatively stronger Australian dollar and on a constant currency basis ARR was $14.9 million.

Summary of cash receipts and outflows

During Q3 FY26 the Company had net cash outflows from operating activities of $4.5 million, net of cash receipts from customers of $3.3 million.

Most of the cash outflows for the quarter relate to staff costs, which totaled $4.5 million, down $0.8 million compared with the previous quarter. The reduction in staffing costs is predominantly due the impact of a relatively stronger Australian dollar as well as the Company's ongoing program to reduce operating costs.

At 31 March 2026, ImpediMed had a total cash balance of $12.7 million representing 2.9 quarters of operating cashflow. Strengthening of the Australian dollar resulted in an unrealised FX loss of $0.7 million. The Company has a fully drawn loan facility of US$15.0 million.

Payments to related parties and their associates during the quarter disclosed in Section 6 of the Appendix 4C totaled $96,000 and comprised payments to Non-Executive Directors.

For more information, contact Investor Relations at investorrelations@impedimed.com.

Approved for release by the Board of ImpediMed Limited

About ImpediMed
Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximise patient health. ImpediMed produces the SOZO® Digital Health Platform, which is FDA-cleared, CE-marked, and ARTG-listed for multiple indications, including lymphoedema, heart failure, and protein calorie malnutrition and sold in select markets globally.

In March 2024, the NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines®) for Survivorship continue to reference bioimpedance spectroscopy as the recommended objective tool to screen at-risk cancer patients for early signs of lymphoedema. With the SOZO Digital Health Platform and L-Dex®, ImpediMed is the only company to offer FDA-cleared technology that uses bioimpedance spectroscopy for the clinical assessment of lymphoedema. The connected digital health platform and large, attractive cancer-related lymphoedema market present an opportunity for continued strong growth through ImpediMed's SaaS subscription-based business.

For more information, visit www.impedimed.com.

Forward looking statements
This announcement contains or may contain forward-looking statements that are based on ImpediMed Limited (ImpediMed) management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to expand sales and market acceptance in the US and Australia including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialise new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position. Any forward-looking statements, including projections, guidance on future revenues, earnings and estimates, are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance.

While management has prepared this information based on its current knowledge and understanding and in good faith, there are risks and uncertainties involved which could cause actual results to differ from projections. You should not place undue reliance on forward-looking statements which speak only as of the date when made. Except as required by law, ImpediMed does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ImpediMed may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements and no representation, warranty or assurance (express or implied) is given or made in relation to any forward-looking statement by any person (including ImpediMed Limited).

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity	
ImpediMed Limited	
ABN	**Quarter ended ("current quarter")**
65 089 705 144	31 March 2026

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (9 months) $A'000**
1.	**Cash flows from operating activities**		
1.1	Receipts from customers	3,268	10,496
1.2	Payments for		
	(a) research and development	(48)	(235)
	(b) product manufacturing and operating costs	(484)	(2,517)
	(c) advertising and marketing	(387)	(840)
	(d) leased assets	-	-
	(e) staff costs	(4,513)	(14,752)
	(f) administration and corporate costs	(2,286)	(6,344)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	-	-
1.5	Interest and other costs of finance paid	-	-
1.6	Income taxes paid	(11)	(11)
1.7	Government grants and tax incentives	-	1,228
1.8	Other (provide details if material)	-	2
1.9	**Net cash from / (used in) operating activities**	**(4,460)**	**(12,973)**

2.	**Cash flows from investing activities**		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	(429)	(904)

Consolidated statement of cash flows		Current quarter $A'000	Year to date (9 months) $A'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	176	638
2.6	**Net cash from / (used in) investing activities**	**(253)**	**(266)**

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	-	7,676
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Interest paid	(733)	(2,184)
3.10	Other (provide details if material)	(91)	(264)
3.11	**Net cash from / (used in) financing activities**	**(824)**	**5,228**

Item 3.9: Cash outflows relate to costs recognised under AASB 16 Leases for the Group's premises leases.

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	18,912	22,249
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(4,460)	(12,973)

Consolidated statement of cash flows		Current quarter $A'000	Year to date (9 months) $A'000
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(253)	(266)
4.4	Net cash from / (used in) financing activities (item 3.11 above)	(824)	5,228
4.5	Effect of movement in exchange rates on cash held	(663)	(1,526)
4.6	**Cash and cash equivalents at end of period**	**12,712**	**12,712**

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter $A'000	Previous quarter $A'000
5.1	Bank balances	1,363	1,207
5.2	Call deposits	11,349	17,705
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**12,712**	**18,912**

6.	Payments to related parties of the entity and their associates	Current quarter $A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1.2	96
6.2	Aggregate amount of payments to related parties and their associates included in item 2.3	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities	21,880	21,880
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	-	-
7.4	**Total financing facilities**	21,880	21,880

7.5	**Unused financing facilities available at quarter end**	-

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

Secured facility with SWK Funding LLC, interest rate 9.5% + 3 months SOFR, maturing on 5 February 2030.

8.	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (item 1.9)	(4,460)
8.2	Cash and cash equivalents at quarter end (item 4.6)	12,712
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	12,712
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)**	2.9

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer: Not applicable

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer: Not applicable

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: Not applicable

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: 30 April 2026

Authorised by: Board of Directors
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.